LAKE FOREST, Calif., June 27 /PRNewswire/ -- Orqis Medical Corporation, a clinical-stage company developing devices for the treatment of heart failure, announced that it has been awarded its 12th U.S. patent, further strengthening its position surrounding novel, proprietary device systems to treat heart failure.
The new patent covers key technology for the company’s Cancion(R) System, an investigational percutaneous treatment for acutely decompensated patients with chronic heart failure. Orqis Medical now has U.S. patents including 197 claims related to methods and apparatus for cardiac devices that supplement blood flow via any peripheral blood vessel to the descending aorta with a percutaneous or implantable system.
“Our comprehensive intellectual property portfolio creates substantial corporate value and it also underscores the breakthrough nature of our technology and approach to treating the millions of people worldwide suffering from heart failure,” said Ken Charhut, President and Chief Executive Officer of Orqis Medical.
About Orqis Medical Corporation
Orqis Medical Corporation is a privately held, clinical-stage medical device company seeking to redefine heart failure therapy by developing products that prevent or reverse underlying disease progression and provide new treatment options to the clinical community to improve patient outcomes and quality of life.
The company’s percutaneous Cancion(R) System, for the treatment of acutely decompensated patients with chronic heart failure, is CE marked and is currently under an investigational device exemption (IDE) investigation in the United States in the pivotal MOMENTUM Trial. The company’s implantable Exeleras(R) System, about the size of an implantable cardiac defibrillator (ICD), is designed to treat mid- to late-stage chronic heart failure patients. First clinical use of this system is planned for the first half of 2007. For more information on Orqis Medical, please visit: www.orqis.com and for the MOMENTUM Trial, please visit: www.momentumtrial.com.
NOTE: ORQIS, CANCION, and EXELERAS are among the trademarks or registered trademarks of ORQIS Medical Corporation.
Orqis Medical Corporation
CONTACT: Brian McIntee, Director of Marketing, +1-949-268-0184, orinvestors, John M. Markovich, Chief Financial Officer, +1-949-268-0552,both of Orqis Medical Corporation
Web site: http://www.orqis.com//
